Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Jul 2018 New trial record